BC
MRNA icon

Brookfield Corp’s Moderna MRNA Stock Holding History

Brookfield Corp’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-40,368
Closed -$6.2M – 706
2023
Q1 		$6.2M Buy
40,368
+12,521
+45% +$2.07M 0.02% 254
2022
Q4 		$5M Buy
27,847
+17,371
+166% +$2.84M 0.02% 268
2022
Q3 		$1.24M Buy
+10,476
New +$1.59M ﹤0.01% 513
2022
Q1 		– Sell
-7,217
Closed -$1.83M – 733
2021
Q4 		$1.83M Buy
7,217
+4,630
+179% +$1.35M 0.01% 345
2021
Q3 		$996K Sell
2,587
-912
-26% -$336K ﹤0.01% 420
2021
Q2 		$822K Buy
+3,499
New +$625K ﹤0.01% 486

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return